CAMBRIDGE, Mass., April 17, 2026
Nuvalent, Inc. has reported compelling clinical and preclinical data for its investigational drug zidesamtinib, highlighting its potential to address significant unmet needs in ROS1-positive non-small cell lung cancer (NSCLC). Presented at the AACR Annual Meeting 2026, the data demonstrate meaningful efficacy in heavily pre-treated patients, including those with central nervous system (CNS) metastases and resistance mutations, reinforcing the drug’s potential as a next-generation targeted therapy.
Strong Clinical Activity in Resistant Patient Populations
The ARROS-1 Phase 1/2 clinical trial results showed that zidesamtinib achieved objective response rates (ORR) of 41% and 47% in patients previously treated with other ROS1 inhibitors such as repotrectinib and taletrectinib. Importantly, patients with the ROS1 G2032R resistance mutation demonstrated response rates as high as 67%, indicating strong efficacy in a population with limited treatment options.
Additionally, the therapy exhibited robust intracranial activity, with intracranial response rates reaching up to 71% in certain patient subgroups. This is particularly significant given the high prevalence of brain metastases in advanced NSCLC, where treatment options remain limited. The data further revealed durable responses with median duration of response extending beyond 15 months, underscoring the potential for long-term disease control.
Equally important, the safety profile of zidesamtinib remained favorable, with low rates of dose reductions and treatment discontinuations, and notably, the absence of TRK-related neurological adverse events, a common limitation in competing therapies.
Advertisement
Differentiated Brain Penetration and Mechanistic Advantage
Preclinical findings presented alongside clinical data demonstrated that zidesamtinib possesses superior brain penetration compared to existing ROS1 inhibitors, a critical factor in treating CNS metastases. The drug showed higher cell permeability and sustained intracranial tumor suppression in preclinical models, with complete survival observed in animal studies.
Designed as a ROS1-selective inhibitor, zidesamtinib avoids inhibition of the tropomyosin receptor kinase (TRK) pathway, thereby reducing the risk of neurological side effects while maintaining high specificity and potency against resistant tumor mutations. This structure-based drug design approach positions the therapy as a potentially best-in-class option for ROS1-driven cancers.
Furthermore, the ability of zidesamtinib to remain active in tumors that have developed resistance to prior therapies highlights its potential role in sequential treatment strategies, extending patient benefit across multiple lines of therapy.